One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (2) · 235-242
DOI: 10.1111/apt.70682 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-04-27. Written by Nicolas Richard and 13 co-authors. Institution: Department of Gastroenterology, University Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen,…. Major MEDLINE topics: Crohn Disease, Heterocyclic Compounds, 3-Ring. Cited 10 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD (pCD) remain limited.
Methods
All consecutive patients with active pCD (primary and/or secondary lesions) treated with UPA across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as absence of fistula drainage (spontaneous or on gentle pressure) and healing of anal ulcerations without initiation of new therapy. Clinical response was defined as ≥ 50% improvement in fistulas and/or ulcerations based on physician assessment. Clinical outcomes were analysed using non‐responder imputation, and magnetic resonance imaging (MRI) outcomes as observed.
Results
Among the 59 patients included, 43 (73%) had fistulizing pCD and 16 (27%) isolated anal ulcerations. All patients were previously exposed to at least one biologic and 79% of those with fistulizing pCD underwent prior perianal surgery. In patients with fistulizing pCD, clinical remission was achieved in 11/43 (26%) and 11/43 (26%) patients at 6 and 12 months, respectively, clinical response in 21/43 (49%) and 13/43 (30%) patients. At 12 months, MRI response was documented in 9/13 (69%) and MRI remission in 1/13 (8%) patients with fistulizing pCD. Among patients with fistulizing pCD, no factors predicted clinical remission. Among patients with isolated anal ulcerations, complete healing occurred in 5/16 (31%) at 3 months, 4/16 (25%) at 6 months and 4/16 (25%) at 12 months.
Conclusion
In this real‐world cohort of refractory pCD, UPA achieved clinical remission in one‐quarter of patients at 1 year.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology, University Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen, France.
- Department of Gastroenterology, CRSA, Sorbonne Université, INSERM UMRS-938, Gut, Liver & Microbiome Research (GLIMMER) FHU, APHP, Saint-Antoine Hospital, Paris, France.
- Department of Gastroenterology, CHU of Montpellier, Montpellier, France.
- University of Lille, INSERM, Lille University Hospital, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
- Department of Gastroenterology, CHU de Bordeaux, Haut-Lévêque Hospital, University of Bordeaux, Bordeaux, France.
- Department of Gastroenterology, Lyon-Sud Hospital, CHU of Lyon, Lyon, France.
ORCID profiles: Nicolas Richard, David Laharie, Anne-Laure Pelletier, Mathieu Uzzan, Aurélien Amiot
Cite
APA
Richard, N., Seksik, P., Altwegg, R., Nachury, M., Laharie, D., Nancey, S., Coffin, B., Pelletier, A. L., Uzzan, M., Amiot, A., Amil, M., Vuitton, L., Fumery, M., & Bozon, A. (2026). One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study. Alimentary Pharmacology & Therapeutics, 64(2), 235-242. https://doi.org/10.1111/apt.70682
Vancouver
Richard N, Seksik P, Altwegg R, Nachury M, Laharie D, Nancey S, et al. One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study. Alimentary Pharmacology & Therapeutics. 2026;64(2):235-242. doi:10.1111/apt.70682
BibTeX
@article{Richard2026,
author = {Richard, Nicolas and Seksik, Philippe and Altwegg, Romain and Nachury, Maria and Laharie, David and Nancey, Stéphane and Coffin, Benoît and Pelletier, Anne-Laure and Uzzan, Mathieu and Amiot, Aurélien and Amil, Morgane and Vuitton, Lucine and Fumery, Mathurin and Bozon, Anne},
title = {One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {2},
pages = {235--242},
doi = {10.1111/apt.70682}
}
EUVIMED